Shell Asset Management Co. lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,987 shares of the pharmaceutical company’s stock after purchasing an additional 1,314 shares during the quarter. Shell Asset Management Co.’s holdings in Vertex Pharmaceuticals were worth $3,677,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in VRTX. Resources Investment Advisors Inc. bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $27,000. FTB Advisors Inc. lifted its position in shares of Vertex Pharmaceuticals by 1,618.2% during the 1st quarter. FTB Advisors Inc. now owns 189 shares of the pharmaceutical company’s stock worth $35,000 after buying an additional 178 shares during the period. We Are One Seven LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $32,000. Berman Capital Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, Sontag Advisory LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $36,000. 96.10% of the stock is currently owned by institutional investors.
VRTX has been the subject of several analyst reports. JPMorgan Chase & Co. restated a “buy” rating and set a $209.00 target price on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 1st. ValuEngine upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Svb Leerink restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, March 19th. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, Cowen restated a “buy” rating and set a $220.00 target price on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seventeen have assigned a buy rating to the company. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $204.36.
In other news, CEO Jeffrey M. Leiden sold 10,480 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $175.08, for a total transaction of $1,834,838.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Stuart A. Arbuckle sold 5,624 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $181.75, for a total value of $1,022,162.00. Following the sale, the executive vice president now owns 36,272 shares of the company’s stock, valued at approximately $6,592,436. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,247 shares of company stock valued at $8,998,147. Corporate insiders own 0.70% of the company’s stock.
Shares of VRTX opened at $171.77 on Friday. The company has a quick ratio of 3.66, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. Vertex Pharmaceuticals Incorporated has a 52-week low of $144.07 and a 52-week high of $195.81. The firm has a market capitalization of $43.99 billion, a price-to-earnings ratio of 60.70, a price-to-earnings-growth ratio of 2.45 and a beta of 1.56.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.49. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The firm had revenue of $857.00 million during the quarter, compared to the consensus estimate of $853.00 million. During the same quarter in the previous year, the company posted $0.76 EPS. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Featured Story: How can investors find ex-dividend dates?
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.